Article
The NDC transition isn't just a pharmacy challenge. It’s a health system one.
Health systems have seven years until the 12-digit National Drug Code deadline—but they should start planning now.
The FDA's mandated transition to a 12-digit National Drug Code (NDC) is slated to begin March 7, 2033, meaning systems should be ready to handle both the 10-and 12-digit numbers once this transition occurs. This shift has been quietly discussed in pharmacy and technology circles for years, but it has yet to find its way into most C-suite conversations. It needs to.
The NDC is not merely a pharmacy identifier. It’s the connective tissue of every medication-related workflow in a health system, touching purchasing, dispensing, billing, and quality reporting. It runs through the EHR, pharmacy management system, revenue cycle systems, claims processing, and the interfaces connecting all of them.
When one step in that system fails, every downstream workflow is affected. This is not a pharmacy automation project. It’s a medication-use workflow update with enterprise-wide implications, and it requires executive-level governance that goes beyond departmental management.
What the transition looks like without a plan
As manufacturers begin shipping products with 12-digit NDCs, an unprepared health system could quickly encounter a cascading series of operational disruptions. Some systems recognize the new format, while others do not. The EHR and billing platform haven't been updated. Barcode scanners fail in some departments, forcing manual receiving processes. Inventory records no longer reconcile automatically. On patient care units, medications fail to scan correctly, creating workarounds that increase safety risks. Claims begin rejecting. Finance feels the impact with reimbursement delays. IT scrambles to build temporary fixes.
The problem is that nearly every medication-related workflow depends on that extra digit. By the time the full scope is evident, the opportunity to respond strategically has closed.
The technology investment required across hundreds of systems will be significant, but manageable if it’s spread across multiple budget cycles. If organizations delay until a compressed two-year implementation window beginning in 2031, the transition could become a budgetary emergency. Health systems will likely compete simultaneously for limited vendor and consulting costs. Meanwhile, labor for project management, workflow redesign, testing, and change management often exceeds the cost of hardware itself. Organizations that begin preparing now can phase investments, spread costs, and reduce risks. Those that wait will lose that flexibility.
Health systems have about seven years to prepare for the new format. Discovery, budgeting, governance, vendor engagement, workflow assessment, and early testing phases should begin well before the 2033 deadline.
The organizations that emerge from this transition the strongest will approach it not as a compliance checkbox, but as an enterprise modernization initiative—one that strengthens interoperability, improves medication safety, and builds the governance capacity that complex multi-system transformations require.
The Federal Drug Administration (FDA) is mandating a shift to a 12-digit National Drug Code (NDC) that takes effect on March 7, 2033 and the FDA has stated that the effective date cannot and will not be extended.
- It's not a pharmacy IT project. The NDC runs through every medication workflow.
- The risk is operational. Systems that have not been appropriately updated are expected to experience rejected claims, manual workarounds, and growing costs.
- Seven years isn't as long as it sounds. Governance, vendor engagement, and testing need to begin early.
The transition is inevitable, and decisions made today will mitigate challenges later.